CA2811744A1 - Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors - Google Patents
Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors Download PDFInfo
- Publication number
- CA2811744A1 CA2811744A1 CA2811744A CA2811744A CA2811744A1 CA 2811744 A1 CA2811744 A1 CA 2811744A1 CA 2811744 A CA2811744 A CA 2811744A CA 2811744 A CA2811744 A CA 2811744A CA 2811744 A1 CA2811744 A1 CA 2811744A1
- Authority
- CA
- Canada
- Prior art keywords
- mrna
- homo sapiens
- aurka
- expression
- gist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10013806 | 2010-10-20 | ||
| EP10013806.4 | 2010-10-20 | ||
| PCT/IB2011/054688 WO2012052954A1 (en) | 2010-10-20 | 2011-10-20 | Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2811744A1 true CA2811744A1 (en) | 2012-04-26 |
Family
ID=44999817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2811744A Abandoned CA2811744A1 (en) | 2010-10-20 | 2011-10-20 | Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130288250A1 (enExample) |
| EP (1) | EP2630259B8 (enExample) |
| JP (1) | JP2014501496A (enExample) |
| CA (1) | CA2811744A1 (enExample) |
| DK (1) | DK2630259T3 (enExample) |
| ES (1) | ES2541054T3 (enExample) |
| WO (1) | WO2012052954A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3064594A1 (en) | 2015-03-06 | 2016-09-07 | Université de Bordeaux | Signature of clinical outcome in uterine smooth muscle tumor analysis, and method of diagnosis thereof |
| KR101860652B1 (ko) | 2015-12-23 | 2018-05-24 | 연세대학교 산학협력단 | 위장관 간질 종양 진단용 마커 및 위장관 간질 종양의 진단 방법 |
| JP6965621B2 (ja) * | 2017-08-02 | 2021-11-10 | 富士通株式会社 | 検出プログラム、検出方法及び検出装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2491067A1 (en) * | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
| JP2008542345A (ja) * | 2005-05-28 | 2008-11-27 | アストラゼネカ アクチボラグ | キナゾリン類及びオーロラキナーゼ阻害剤としてのその使用 |
| EP1896462A2 (en) * | 2005-05-31 | 2008-03-12 | The Pfahl Family Trust (Dated 9 July 1996) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
| WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
| EP2468887A1 (en) * | 2006-12-13 | 2012-06-27 | Oncotherapy Science, Inc. | TTK as tumor marker and therapeutic target for lung cancer |
| PE20090365A1 (es) * | 2007-06-14 | 2009-04-04 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| US9101631B2 (en) * | 2008-12-12 | 2015-08-11 | Georgetown University | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer |
-
2011
- 2011-10-20 DK DK11785107.1T patent/DK2630259T3/en active
- 2011-10-20 ES ES11785107.1T patent/ES2541054T3/es active Active
- 2011-10-20 EP EP11785107.1A patent/EP2630259B8/en not_active Not-in-force
- 2011-10-20 WO PCT/IB2011/054688 patent/WO2012052954A1/en not_active Ceased
- 2011-10-20 CA CA2811744A patent/CA2811744A1/en not_active Abandoned
- 2011-10-20 US US13/880,155 patent/US20130288250A1/en not_active Abandoned
- 2011-10-20 JP JP2013534446A patent/JP2014501496A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014501496A (ja) | 2014-01-23 |
| US20130288250A1 (en) | 2013-10-31 |
| WO2012052954A1 (en) | 2012-04-26 |
| EP2630259A1 (en) | 2013-08-28 |
| DK2630259T3 (en) | 2015-07-06 |
| EP2630259B1 (en) | 2015-04-15 |
| ES2541054T3 (es) | 2015-07-15 |
| EP2630259B8 (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Childs et al. | Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma | |
| Toda et al. | RNA‐sequence‐based microRNA expression signature in breast cancer: tumor‐suppressive miR‐101‐5p regulates molecular pathogenesis | |
| Feber et al. | MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma | |
| EP2714926B1 (en) | Biomarkers for lung cancer | |
| Bjaanæs et al. | Unique microRNA‐profiles in EGFR‐mutated lung adenocarcinomas | |
| US20170107577A1 (en) | Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment | |
| Xiao et al. | Aberrant expression of microRNA‐15a and microRNA‐16 synergistically associates with tumor progression and prognosis in patients with colorectal cancer | |
| Pedersen et al. | MicroRNA-based classifiers for diagnosis of oral cavity squamous cell carcinoma in tissue and plasma | |
| Colombo et al. | Gene expression profiling reveals molecular marker candidates of laryngeal squamous cell carcinoma | |
| Watanabe et al. | Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways | |
| Hu et al. | MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma | |
| CA2852384C (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| Gyvyte et al. | MiRNA profiling of gastrointestinal stromal tumors by next-generation sequencing | |
| Ju et al. | Altered expression pattern of circular RNAs in metastatic oral mucosal melanoma | |
| Men et al. | Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients | |
| WO2013130748A1 (en) | Prostate cancer markers and uses thereof | |
| Brito et al. | Identification of protein‐coding and intronic noncoding RNAs down‐regulated in clear cell renal carcinoma | |
| Binato et al. | A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis | |
| CA2695814A1 (en) | Methods and tools for prognosis of cancer in her2+ patients | |
| EP2283161A2 (en) | Methods for assessing colorectal cancer and compositions for use therein | |
| Iorio et al. | MicroRNA profiling in ovarian cancer | |
| EP2630259B1 (en) | Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors | |
| CN106715722A (zh) | 用于评价化学放射线疗法对鳞状细胞癌的有效性的方法 | |
| US9708666B2 (en) | Prognostic molecular signature of sarcomas, and uses thereof | |
| EP3677694B1 (en) | Compositions and methods for the analysis of radiosensitivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20171020 |